The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
L | Antineoplastic and immunomodulating agents | |
2
|
L01 | Antineoplastic agents | |
3
|
L01X | Other antineoplastic agents | |
4
|
L01XM | Isocitrate dehydrogenase (IDH) inhibitors | |
5
|
L01XM02 |
| Active Ingredient |
|---|
|
Ivosidenib is an inhibitor of the mutant IDH1 enzyme. Mutant IDH1 converts alpha- ketoglutarate (αKG) to 2-hydroxyglutarate (2-HG) which blocks cellular differentiation and promotes tumorigenesis in both hematologic and non-hematologic malignancies. The mechanism of action of ivosidenib beyond its ability to reduce 2-HG and restore cellular differentiation is not fully understood across indications. |
| Document | Type | Information Source | |
|---|---|---|---|
| TIBSOVO Film-coated tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| TIBSOVO Film-coated tablet | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.